Background
Treatment of end-stage heart failure has markedly evolved. With only a limited number of available heart transplants (24 in 2012) in our institution, mechanical circulatory support (MCS) has become an integral part of acute and end-stage heart failure treatment and has improved survival. We report our experience in MCS program since 2008. 
Methods

Results
In the adult group, 66% of patients were at INTER-MACS level 1, critical cardiogenic shock, and 19% were at level 2, progressive decline. Indications for primary MCS included: acute exacerbation of chronic heart failure, acute cardiogenic shock and respiratory failure. Altogether, procedural success was accomplished in 49.4% of patients. MCS efficiently bridged 14 patients with heart failure to heart transplantation. In 15 patients, long term support was instituted, either as a destination therapy or as a bridge to heart transplant; 13 received HeartMate II, and 2 patients received Heart-Ware. One patient with respiratory failure was successfully bridged to lung transplantation. In the pediatric group, 60% patients were bridged to recovery. Postcardiotomy MCS was used in 33.7% patients. Patient outcome after 30 days was assessed as: alive (22.4%), alive on support (13.5%), dead (64.0%). The most common perioperative complication was renal failure, in 42.7% patients.
Conclusion
MCS has become an integral part of terminal stage heart failure treatment alongside established standard procedures.
